Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC1203 in Allergic Rhinitis
NCT01614691Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Jun 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SPARC1203 in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Sun Pharma. Primary endpoint: Total Nasal Symptom Score at 2 weeks. Started Jun 2012; status: completed.
02
Drugs
SPARC1203
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT01614691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614691.